Clinical Trials Directory

Trials / Unknown

UnknownNCT05471713

MAPT Haploid H1b and the Damage of BBB in Dorsal Medulla Oblongata and Autonomic Dysfunction in PD

Study on the Correlation Between MAPT Haploid H1b and the Damage of Blood-brain Barrier in Dorsal Medulla Oblongata and Autonomic Dysfunction in Parkinson's Disease

Status
Unknown
Phase
Study type
Observational
Enrollment
80 (estimated)
Sponsor
Zhujiang Hospital · Academic / Other
Sex
All
Age
45 Years
Healthy volunteers
Not accepted

Summary

This study mainly explored the relationship between the permeability of the blood-brain barrier in the dorsal medulla oblongata and autonomic dysfunction, and the relationship and mechanism of MAPT genotype on the permeability of the blood-brain barrier and the progression of autonomic dysfunction in PD patients.

Detailed description

According to the MDS 2015 clinical diagnostic criteria for Parkinson's disease and the diagnostic criteria for autonomic dysfunction (AutD), the patients were divided into PD with AutD group and PD without AutD group. DCE results, pet-pdrp+18f-dopa data and clinical evaluation (SCOPA-AUT, HRV and sleep EEG) were analyzed; Blood samples were collected to detect MAPT gene polymorphism, oligomers and phosphorylated synuclein. To explore the relationship between the permeability of the blood-brain barrier in the dorsal medulla oblongata and autonomic dysfunction, and the relationship and mechanism of MAPT genotype on the permeability of the blood-brain barrier and the progression of autonomic dysfunction in PD patients.

Conditions

Interventions

TypeNameDescription
OTHERAutonomic dysfunctionAutonomic dysfunction

Timeline

Start date
2022-01-01
Primary completion
2023-12-30
Completion
2023-12-30
First posted
2022-07-25
Last updated
2022-07-25

Locations

1 site across 1 country: China

Source: ClinicalTrials.gov record NCT05471713. Inclusion in this directory is not an endorsement.